18F-FDG PET/CT reveals disease remission in a patient with ipilimumab-refractory advanced melanoma treated with pembrolizumab
Pembrolizumab is an anti-programmed cell death receptor 1 (anti-PD-1) antibody, recently approved for the treatment of ipilimumab-refractory metastatic melanoma. We report on a 49-year-old patient with unresectable metastatic melanoma initially treated with 4 cycles of ipilimumab. Because of demonst...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
February 2016
|
| In: |
Clinical nuclear medicine
Year: 2016, Volume: 41, Issue: 2, Pages: 156-158 |
| ISSN: | 1536-0229 |
| DOI: | 10.1097/RLU.0000000000001039 |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1097/RLU.0000000000001039 Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/nuclearmed/fulltext/2016/02000/18F_FDG_PET_CT_Reveals_Disease_Remission_in_a.13.aspx 
|
| Author Notes: | Christos Sachpekidis, Jessica C. Hassel, and Antonia Dimitrakopoulou-Strauss |
| Summary: | Pembrolizumab is an anti-programmed cell death receptor 1 (anti-PD-1) antibody, recently approved for the treatment of ipilimumab-refractory metastatic melanoma. We report on a 49-year-old patient with unresectable metastatic melanoma initially treated with 4 cycles of ipilimumab. Because of demonstration of progressive disease on PET/CT, the patient was enrolled into a clinical trial of pembrolizumab. After completion of 4 cycles of pembrolizumab, the follow-up PET/CT scans performed early after and 7 months after the end of treatment exhibited complete disease remission, reflecting the potential role of the modality in treatment response evaluation of melanoma patients receiving anti-PD-1 therapy. |
|---|---|
| Item Description: | Gesehen am 07.05.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1536-0229 |
| DOI: | 10.1097/RLU.0000000000001039 |